Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis

Catherine R. Jutzeler, Lucie Bourguignon, Caroline Weis, Bobo Tong, Ka Wo Wong, Bastian Rieck, Hans Pargger, Sarah Tschudin‐Sutter, Adrian Egli, Karsten Borgwardt, Matthias WaltermedRxiv 2020 · DOI

Abstract

Since the emergence of SARS-CoV-2 in late 2019, the global medical community has sought to identify the clinical markers and risk factors that define COVID-19 severity. This systematic review and meta-analysis synthesizes data from 148 early-pandemic studies involving 12,149 patients. The findings identify older age, male sex, and pre-existing comorbidities—particularly cardiovascular and respiratory conditions—as primary drivers of mortality. Conversely, pediatric and pregnant populations demonstrated lower vulnerability. This paper provides a comprehensive baseline of clinical symptoms, laboratory markers, and imaging features that characterized the first wave of the pandemic.

Introduction

In the initial months of the COVID-19 pandemic, healthcare providers faced a deluge of fragmented data. While individual case reports provided anecdotal evidence, there was an urgent need for a high-level synthesis to guide clinical decision-making and public health policy. This study addresses that need by aggregating evidence from the first 120 days of the outbreak, focusing on the clinical spectrum of the disease across diverse patient cohorts, including adults, children, and pregnant women.

Methodology

The researchers conducted a systematic review and meta-analysis in accordance with PRISMA and MOOSE guidelines. A comprehensive search of EMBASE, PubMed/Medline, Scopus, and Web of Science was performed for studies published between December 1, 2019, and March 28, 2020.

To account for the inherent variability in study designs and patient populations, the authors employed random-effects pairwise meta-analyses. This statistical approach allowed for the calculation of risk ratios (RR) and standardized mean differences (SMD) while addressing "heterogeneity"—the statistical noise (measured via I², Tau², and Cochrane Q) resulting from geographic and demographic differences. Data were stratified by cohort (adult vs. pediatric) and outcome (survivors vs. non-survivors).

Data Overview

The meta-analysis aggregated data from 148 peer-reviewed original studies, representing a total population of 12,149 confirmed COVID-19 patients.

  • Demographics: The median age was 47.0 years, with a nearly even gender distribution (5,739 females).
  • Geographic Focus: Reflecting the early epicenter of the virus, 129 of the 148 studies were conducted in China.
  • Outcomes: Among the total cohort, 617 deaths were recorded, while 297 patients were identified as asymptomatic at the time of reporting.

Key Results and Clinical Findings

Risk Factors for Mortality

The study identified three primary predictors of in-hospital mortality:

  1. Older Age: (SMD: 1.25; p < 0.001)
  2. Male Sex: Men faced a significantly higher risk of death (RR = 1.32; p = 0.005) and accounted for 52.8% of infections.
  3. Pre-existing Comorbidities: The presence of any underlying condition increased the risk of death (RR = 1.69; p < 0.001).

Impact of Specific Comorbidities

Certain pre-existing conditions were more strongly associated with severe disease progression than others. The risk ratios for developing severe COVID-19 were:

  • COPD: RR = 5.10
  • Heart Conditions: RR = 4.09
  • Diabetes Mellitus: RR = 2.56
  • Hypertension: RR = 2.15

Clinical Presentation and Imaging

Fever (78.5%) and cough (53.8%) remained the hallmark symptoms in adult patients. However, imaging proved to be a more sensitive diagnostic tool than clinical symptoms alone; CT scans showed abnormalities in nearly 90% of adult patients, including those who were otherwise asymptomatic. The most lethal complication identified was Acute Respiratory Distress Syndrome (ARDS), with non-survivors being over four times more likely to develop the condition than survivors.

Discussion: Vulnerable and Protected Populations

The "Male Disadvantage"

The consistent finding that men were more likely to suffer severe outcomes suggests a combination of biological and lifestyle factors. The authors hypothesize that the expression of the ACE2 receptor, which the virus uses for entry, may differ by sex, alongside variations in immune response.

The Pediatric Shield

One of the most striking findings was the relative resilience of children and neonates. Only one pediatric death was reported in the analyzed data, and 14% of children were entirely asymptomatic. This suggests a different immune interaction or lower viral susceptibility in younger populations during the initial wave.

Laboratory Biomarkers

The meta-analysis identified specific laboratory "red flags" that correlated with disease severity. Patients with poor prognoses typically exhibited:

  • Elevated Inflammatory Markers: C-reactive protein (CRP) and lactate dehydrogenase (LDH).
  • Depleted Levels: Significantly lower levels of albumin and hemoglobin compared to patients with mild cases.

Limitations and Conclusion

While this study provides a robust baseline, it is limited by the geographical concentration of data in China, which may affect generalizability to other healthcare systems. Additionally, early reporting bias—where clinicians may not have recorded the absence of symptoms—could distort some proportions.

In conclusion, this meta-analysis confirms that COVID-19 severity is heavily dictated by age, sex, and specific chronic conditions. These findings underscore the importance of targeted protection for high-risk groups and the utility of specific laboratory markers in triaging patients. Future research should prioritize sex-disaggregated data and longitudinal studies on the long-term effects of the virus across different age groups.

Summary updated

Abstract

Introduction Since December 2019, a novel coronavirus (SARS-CoV-2) has triggered a world-wide pandemic with an enormous medical, societal, and economic toll. Thus, our aim was to gather all available information regarding comorbidities, clinical signs and symptoms, outcomes, laboratory findings, imaging features, and treatments in patients with coronavirus disease 2019 (COVID-19). Methods EMBASE, PubMed/ Medline, Scopus, and Web of Science were searched for studies published in any language between December 1st, 2019 and March 28th. Original studies were included if the exposure of interest was an infection with SARS-CoV-2 or confirmed COVID-19. The primary outcome was the risk ratio of comorbidities, clinical signs and symptoms, imaging features, treatments, outcomes, and complications associated with COVID-19 morbidity and mortality. We performed random-effects pairwise meta-analyses for proportions and relative risks, I2, Tau2, and Cochrane Q, sensitivity analyses, and assessed publication bias. Results: 148 met the inclusion criteria for the systematic review and meta-analysis with 12149 patients (5739 female) and a median age was 47.0 [35.0-64.6]. 617 patients died from COVID-19 and its complication, while 297 patients were reported as asymptomatic. Older age (SMD: 1.25 [0.78- 1.72]; p &lt; 0.001), being male (RR = 1.32 [1.13-1.54], p = 0.005) and pre-existing comorbidity (RR = 1.69 [1.48-1.94]; p &lt; 0.001) were identified as risk factors of in-hospital mortality. The heterogeneity between studies varied substantially (I2; range: 1.5-98.2%). Publication bias was only found in eight studies (Eggers test: p &lt; 0.05). Conclusions: Our meta-analyses revealed important risk factors that are associated with severity and mortality of COVID-19.
BibTeX
@misc{jutzeler2020comorbidities,
  author = {Catherine R. Jutzeler and Lucie Bourguignon and Caroline Weis and Bobo Tong and Ka Wo Wong and Bastian Rieck and Hans Pargger and Sarah Tschudin‐Sutter and Adrian Egli and Karsten Borgwardt and Matthias Walter},
  title = {{Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis}},
  year = {2020},
  doi = {10.1101/2020.05.20.20103804},
  howpublished = {medRxiv},
}
Figure